TNF and neoplasm: A third phase II trial looked at DCs loaded with tumor lysate antigens, matured by exposure to prostaglandin E2 (PGE2) and tumor necrosis factor-α (TNF-α), and injected directly into cervical lymph nodes (NCT00323115).